LianMedical 

LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for cholangiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.